Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells
Endocrine-Related Cancer · 01.06.2023 · 30 (9)
DOI: 10.1530/erc-23-0130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, erschienen am 01.06.2023. Verfasst von Guo-Qiang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Symporters. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Radioiodine treatment is a fundamental therapy for patients with papillary thyroid cancer (PTC). Sodium/iodide symporter (NIS)-mediated iodine uptake is a prerequisite for the efficacy of radioiodine therapy. Interleukin-6 (IL-6) is a pro-tumor cytokine, but its regulation of NIS expression in PTC has not been elucidated. In this study, we found that IL-6 enhanced the proliferation ability of PTC cells. Moreover, the negative association between IL-6 and NIS expression in thyroid cancer tissues was demonstrated. IL-6 downregulated thyroid-specific genes such as NIS, thyroid peroxidase, and thyroid-stimulating hormone receptor and thyroid-specific transcription factors including thyroid transcription factor-1 (TTF-1) and paired box protein-8 (PAX-8). The inhibitory effects of IL-6 on NIS expression were alleviated by mitogen-activated protein kinase and Janus kinase inhibitors. Depletion of c-Jun or STAT3 also rescued IL-6-induced NIS downregulation, with STAT3 depletion exerting a stronger effect. TTF-1 protein expression was also restored by depleting c-Jun or STAT3. STAT3 depletion, but not c-Jun depletion, alleviated the inhibitory effect of IL-6 on PAX-8 expression. Moreover, the downregulation of NIS by IL-6 was rescued by overexpressing TTF-1 and PAX-8. Tocilizumab, an IL-6 receptor blocker, did not have any cytostatic activity in PTC cells, and it also failed to induce redifferentiation in vitro . However, we found that the drug blocked the inhibitory effect of IL-6 on NIS expression. In summary, IL-6 inhibits NIS transcription in PTC cells by activating mitogen-activated protein kinase and Janus kinase signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Quan-Yong Luo
Zitieren
APA
Zhang, G. Q., Xi, C., Shen, C. T., Song, H. J., Luo, Q. Y., & Qiu, Z. L. (2023). Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. Endocrine-Related Cancer, 30(9). https://doi.org/10.1530/erc-23-0130
Vancouver
Zhang GQ, Xi C, Shen CT, Song HJ, Luo QY, Qiu ZL. Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. Endocrine-Related Cancer. 2023;30(9). doi:10.1530/erc-23-0130
BibTeX
@article{Zhang2023,
author = {Zhang, Guo-Qiang and Xi, Chuang and Shen, Chen-Tian and Song, Hong-Jun and Luo, Quan-Yong and Qiu, Zhong-Ling},
title = {Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells},
journal = {Endocrine-Related Cancer},
year = {2023},
volume = {30},
number = {9},
doi = {10.1530/erc-23-0130}
}
EUVIMED